Entering text into the input field will update the search result below Entering text into the input field will update the search result below ...
Switzerland-based biopharma start-up Enzyvant has gained a double fast track status from the FDA for its new rare disease candidate RVT-802. The investigational tissue-based therapy is for the ...
Roche has announced a $7.1 billion deal to acquire Roivant group company Telavant and its RVT-301 drug candidate for inflammatory bowel disease (IBD), confirming rumours that have been swirling around ...
Abstract: Unmanned aerial vehicles (UAVs) have found numerous applications and are expected to bring fertile business opportunities in the next decade. Among various enabling technologies for UAVs, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results